YOLFTbeta
66

Anxo Pharmaceutical Co., Ltd.

6677 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

20.65TWD-0.05 (-0.24%)

Price History

Full chart

Market Stats

Previous Close20.70
Open20.70
Day Range20.45 – 21.30
52-Week Range15.50 – 27.25
Volume80.23K
Market Cap1.06B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.37
Dividend Yield0.00%
Beta0.31
50-Day Avg17.35
200-Day Avg18.37

About

Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, orthopedics, etc. It also offers drugs for antidiabetic/dyslipidaemic agents, cardiovascular/circulatory system, nervous system, hepatology/gastroenterology, anti-infectives/anti-viruses, hemodialysis/urinary system, respiratory system/antihistamine, analgesics, and others; and injections. The company was founded in 2003 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOLinquan Yan
  • HeadquartersNo. 206, Nanjing East Road, Taipei, Taiwan, 10489, Taiwan
  • Websitehttps://www.anxo.com.tw

Leadership

  • Linquan YanManager & Director
  • Mr. Zhixian ChenChief Financial Officer
  • Wenlong LiAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue877.93M866.11M824.10M866.27M939.94M895.32M843.26M
Growth (%)--1.35%-4.85%+5.12%+8.50%-4.75%-5.81%
Cost of Revenue558.66M509.82M492.44M534.82M543.01M569.84M543.09M
Gross Profit319.27M356.29M331.66M331.46M396.93M325.48M300.18M
Gross Margin36.37%41.14%40.24%38.26%42.23%36.35%35.60%
Operating Expense273.88M299.17M291.56M325.51M343.78M381.91M343.08M
Operating Income45.40M57.12M40.10M5.95M53.15M-56.42M-42.91M
Operating Margin5.17%6.60%4.87%0.69%5.65%-6.30%-5.09%
EBITDA117.08M144.25M111.22M84.96M131.31M33.37M47.24M
EBITDA Margin13.34%16.65%13.50%9.81%13.97%3.73%5.60%
Net Income24.12M31.40M19.23M-12.56M21.86M-57.21M-34.13M
Net Income Margin2.75%3.63%2.33%-1.45%2.33%-6.39%-4.05%
R&D66.74M100.56M111.38M139.59M139.20M148.43M131.11M
R&D as % of Total Revenue7.60%11.61%13.52%16.11%14.81%16.58%15.55%
Interest Expense16.81M14.19M12.76M15.19M18.07M16.68M16.64M
Interest Expense % of Total Revenue1.92%1.64%1.55%1.75%1.92%1.86%1.97%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.91B1.91B1.92B1.97B2.22B2.11B2.07B
Total Liabilities1.22B1.10B1.09B1.14B1.02B968.21M958.70M
Total Equity597.55M713.01M732.96M724.86M1.09B1.02B991.76M
Cash177.63M207.76M214.18M241.32M295.43M358.92M363.37M
Total Debt985.55M890.40M883.44M888.05M787.84M726.77M-
Net Debt807.92M682.64M669.25M646.73M492.41M367.86M352.03M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow64.48M59.88M78.35M71.27M-2.65M111.97M55.34M
Investing Cash Flow-38.16M-11.89M-37.36M-22.41M-179.24M35.26M-
Financing Cash Flow-2.57M-17.86M-34.57M-21.72M236.01M-83.75M-
Capital Expenditure23.09M15.98M33.90M16.62M58.04M60.59M49.40M
Free Cash Flow41.39M43.90M44.45M54.65M-60.70M51.38M5.93M
Dividends Paid-11.47M---22.25M-
FCF to OCF64.19%73.32%56.73%76.68%2286.10%45.89%10.73%
Dividend Paid to FCF-26.12%---43.31%-

Key Statistics & Ratios

Market Cap1.06B
Enterprise Value1.49B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.21
Price / Book1.09
EPS-0.37
Book Value17.60
Revenue (TTM)878.88M
Gross Profit (TTM)323.15M
EBITDA36.38M
Profit Margin-2.33%
Operating Margin-1.91%
Return on Equity-1.99%
Return on Assets-0.78%
Shares Outstanding55.98M
Shares Float27.10M
Beta0.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.40Aug 26, 2024
20201×
0.23Jul 2, 2020

Stock Splits

  • Nov 1, 20211050:1000
  • Jul 15, 20191030:1000